The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Current approaches to cardiovascular risk management in patients with ischemic stroke. (Press-Release) Proceedings of the Symposium on October 28, 2021 at the Interregional Scientific-Practical Conference with International Participation "Stroke: an Interdisciplinary Problem

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12‑2): 77‑80

DOI: 10.17116/jnevro202112112277

Read: 1320 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT APPROACHES TO CARDIOVASCULAR RISK MANAGEMENT IN PATIENTS WITH ISCHEMIC STROKE. (PRESS-RELEASE) PROCEEDINGS OF THE SYMPOSIUM ON OCTOBER 28, 2021 AT THE INTERREGIONAL SCIENTIFIC-PRACTICAL CONFERENCE WITH INTERNATIONAL PARTICIPATION "STROKE: AN INTERDISCIPLINARY PROBLEM
CURRENT APPROACHES TO CARDIOVASCULAR RISK MANAGEMENT IN PATIENTS WITH ISCHEMIC STROKE. (PRESS-RELEASE) PROCEEDINGS OF THE SYMPOSIUM ON OCTOBER 28, 2021 AT THE INTERREGIONAL SCIENTIFIC-PRACTICAL CONFERENCE WITH INTERNATIONAL PARTICIPATION "STROKE: AN INTERDISCIPLINARY PROBLEM

To cite this article:

Current approaches to cardiovascular risk management in patients with ischemic stroke. (Press-Release) Proceedings of the Symposium on October 28, 2021 at the Interregional Scientific-Practical Conference with International Participation "Stroke: an Interdisciplinary Problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12‑2):77‑80. (In Russ.)
https://doi.org/10.17116/jnevro202112112277

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Current approaches to cardiovascular risk management in patients with ischemic stroke. (Press-Release) Proceedings of the Symposium on October 28, 2021 at the Interregional Scientific-Practical Conference with International Participation "Stroke: an Interdisciplinary Problem.

Close metadata

References:

  1. Truelsen T, Bonita R. The worldwide burden of stroke: current status and future projections. Handbook of clinical neurology. Amsterdam: Elsevier. 2008;92:327-336.  https://doi.org/10.1016/S0072-9752(08)01916-7
  2. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.  https://doi.org/10.1016/S0140-6736(15)60692-4
  3. Feigin VL, Krishnamurthi RV, Parmar P, et al. GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161-176.  https://doi.org/10.1159/000441085
  4. Lakshminarayan K, Schissel C, Anderson DC, et al. Five-Year Rehospitalization Outcomes in a Cohort of Patients with Acute Ischemic Stroke. Stroke. 2011;42:1556-1562. https://doi.org/10.1161/STROKEAHA.110.605600
  5. Crichton SL, Bray BD, McKevitt C, et al. Patient outcomes up to 15 years after stroke: survival, disability, quality of life, cognition and mental health. J Neurol Neurosurg Psychiatry. 2016;87(10):1091-1098. https://doi.org/10.1136/jnnp-2016-313361
  6. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.  https://doi.org/10.1016/j.jacc.2017.04.052
  7. National Stroke Association. Medical Risk Factors. https://www.stroke.org/en/about-stroke/stroke-risk-factors
  8. Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30(4):520-529.  https://doi.org/10.1002/humu.20882
  9. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928-933.  https://doi.org/10.1073/pnas.0335507100
  10. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(suppl):172-177.  https://doi.org/10.1194/jlr.R800091-JLR200
  11. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. https://doi.org/10.1001/jama.2016.16951
  12. Sabatine MS, Giugliano RP, Keech A, et al. FOURIER Steering Committee and Investigators. N Engl J Med. 2017;376(18):1713-1722. https://doi.org/10.1056/NEJMoa1615664
  13. Giugliano RP, Pedersen TR, Saver JL, et al. FOURIER Investigators. Stroke Prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020;51(5):1546-1554. https://doi.org/10.1161/STROKEAHA.119.027759
  14. Giugliano RP, Mach Fs, Kenton Z, et al. EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633-643.  https://doi.org/10.1056/NEJMoa1701131
  15. Sabatine MS, De Ferrari GM, Giugliano R, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Circulation. 2018;138(8):756-766.  https://doi.org/10.1161/CIRCULATIONAHA.118.034309
  16. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering with Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-350.  https://doi.org/10.1161/CIRCULATIONAHA.117.032235
  17. Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term Efficacy and Safety of Evolocumab in Patients with Hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132-2146. https://doi.org/10.1016/j.jacc.2019.08.1024
  18. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962-1971. https://doi.org/10.1016/S0140-6736(17)32290-0
  19. Powers WJ, Rabinstein AA, Ackerson T, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):46-110.  https://doi.org/10.1161/STR.0000000000000158
  20. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188.  https://doi.org/10.1093/eurheartj/ehz455
  21. Vozniuk IA, Shamalov NA, Ezhov MV, et al. Optimization of lipid-lowering therapy in patients after ischemic stroke. Resolution of the Council of Experts. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(6):152-161. (In Russ.). https://doi.org/10.17116/jnevro2020120061152
  22. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):364-467.  https://doi.org/10.1161/STR.0000000000000375
  23. Reiner Ž, De Backer G, Fras Z, et al. EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries — Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243-250.  https://doi.org/10.1016/j.atherosclerosis.2016.01.018
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.